Alder BioPharmaceuticals Inc. revealed that an intravenous injection of its lead clinical candidate ALD403 was found to be validated against migraine attacks, an annoying and recurring headache that can cause nausea and blurred vision. The 300 mg and 100 mg doses found to reduce the average number of migraine by 75 percent in up to 33 percent and 31 percent of patients, respectively. The study has